Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2017—Enzo Life Sciences unveiled its Multiview Plus (mouse-HRP/rabbit-AP) IHC Kit (brown/green). This nonbiotin nanopolymer detection system contains reagents and materials that detect and localize antigens in formalin-fixed, paraffin-embedded tissues. The kit optimizes the IHC process by including the entire workflow, from antigen retrieval to visualization.
July 2017—MDxHealth SA announced that results from a retrospective study demonstrated that its ConfirmMDx for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy. The study findings were presented in a podium session at the 2017 American Urological Association annual meeting in Boston.
July 2017—Roche announced the CE-IVD launch of the Cobas Liat PCR System with four assays, including a 20-minute real-time PCR nucleic acid test to detect Clostridium difficile.
July 2017—Cynvenio Biosystems announced the availability of ClearID Total Insight Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
July 2017—Swift Biosciences has commercially released its Accel-Amplicon CFTR Panel, which aims to provide research laboratories with a more comprehensive, next-generation sequencing–based approach to interrogate the coding region and select introns within the cystic fibrosis transmembrane conductance regulator gene for disease-relevant mutations and variants. The panel is designed to offer a higher resolution view into the CFTR gene and produces ready-to-sequence libraries in two hours.
July 2017—Olympus’ new BX53 microscope features an LED illuminator equivalent to a 100-watt halogen lamp that delivers outstanding brightness and true-to-life images, according to the company. The LED enables researchers to clearly see purple, cyan, and pink dyes while its consistent color temperature aims to help speed up the observation workflow, since users don’t have to take time adjusting a color filter. The coded nosepiece works with the light intensity manager to automatically adjust the brightness level based on the objective being used.
June 2017—LGC Maine Standards’ Validate Heparin calibration verification/linearity test kit received FDA 510(k) clearance for use on Instrumentation Laboratory’s ACL TOP 500 hemostasis test systems. The Validate Heparin kit evaluates heparin anti-Xa activity in a human plasma matrix, is prepared using CLSI’s EP06-A recommended equal delta method for linearity testing, and is liquid, ready to use.
June 2017—Roche announced the CE-IVD launch of Cobas HPV for use on the Cobas 6800/8800 Systems for cervical cancer screening. This HPV DNA assay gives laboratories the ability to run HPV DNA testing simultaneously with other previously released Cobas assays, including chlamydia and gonorrhea (CT/NG), HIV-1, HCV, HBV, CMV, and three next-generation assays for donor screening: the Cobas MPX, Cobas WNV, and Cobas HEV.
June 2017—Cofactor Genomics launched its Pinnacle assay, which looks at gene fusions and gene expression in patient tumor samples to provide physicians with potential treatment targets for cancer patients.
June 2017—Singulex announced it received the CE mark for the Sgx Clarity system, a fully automated in vitro diagnostics platform powered by single-molecule counting technology. Up to 1,000 times more sensitive than existing technologies, single- molecule counting technology measures biomarkers at the lowest levels, revealing the presence, or absence, of disease so clinicians can provide the right treatment at the right time.
